Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Foltynie

Showing results (11-20 of 259) with videos related to

Pageof 26
Sort By:
CNS Drugs|August 2, 2018
Drug Repurposing in Parkinson's DiseaseDilan Athauda, Thomas Foltynie
Nature Reviews. Neurology|December 3, 2014
The ongoing pursuit of neuroprotective therapies in Parkinson diseaseDilan Athauda, Thomas Foltynie
Brain : a Journal of Neurology|August 3, 2023
How should we be using biomarkers in trials of disease modification in Parkinson's disease?Nirosen Vijiaratnam, Thomas Foltynie
Brain : a Journal of Neurology|January 12, 2018
Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's diseaseJames P Gratwicke, Thomas Foltynie
Expert Review of Neurotherapeutics|June 4, 2010
Surgical management of Parkinson's diseaseThomas Foltynie, Marwan I Hariz
Journal of Neurology|October 22, 2010
Gene therapy: a viable therapeutic strategy for Parkinson's disease?Alexander L Berry, Thomas Foltynie
Journal of Neurology|March 12, 2004
The future challenges in Parkinson's diseaseRoger A Barker, Thomas Foltynie
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 18, 2014
Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinicThomas Foltynie, Iciar Aviles-Olmos
Brain : a Journal of Neurology|April 19, 2015
Parkinson's disease dementia: a neural networks perspectiveJames Gratwicke, Marjan Jahanshahi, Thomas Foltynie
Journal of Parkinson'S Disease|May 17, 2017
Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation ParametersViswas Dayal, Patricia Limousin, Thomas Foltynie
Pageof 26

Showing results (11-20 of 259) with videos related to

Sort By:
Pageof 26
CNS Drugs|August 2, 2018
Drug Repurposing in Parkinson's DiseaseDilan Athauda, Thomas Foltynie
Nature Reviews. Neurology|December 3, 2014
The ongoing pursuit of neuroprotective therapies in Parkinson diseaseDilan Athauda, Thomas Foltynie
Brain : a Journal of Neurology|August 3, 2023
How should we be using biomarkers in trials of disease modification in Parkinson's disease?Nirosen Vijiaratnam, Thomas Foltynie
Brain : a Journal of Neurology|January 12, 2018
Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's diseaseJames P Gratwicke, Thomas Foltynie
Expert Review of Neurotherapeutics|June 4, 2010
Surgical management of Parkinson's diseaseThomas Foltynie, Marwan I Hariz
Journal of Neurology|October 22, 2010
Gene therapy: a viable therapeutic strategy for Parkinson's disease?Alexander L Berry, Thomas Foltynie
Journal of Neurology|March 12, 2004
The future challenges in Parkinson's diseaseRoger A Barker, Thomas Foltynie
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 18, 2014
Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinicThomas Foltynie, Iciar Aviles-Olmos
Brain : a Journal of Neurology|April 19, 2015
Parkinson's disease dementia: a neural networks perspectiveJames Gratwicke, Marjan Jahanshahi, Thomas Foltynie
Journal of Parkinson'S Disease|May 17, 2017
Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation ParametersViswas Dayal, Patricia Limousin, Thomas Foltynie
Pageof 26